Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Inventiva社がNASHおよび2型糖尿病（T2D）患者を対象とした、lanifibranorとエンパグリフロジンの併用によるフェーズⅡa試験、LEGENDにおける初回被験者のスクリーニングを発表
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH